Day One Biopharmaceuticals, Inc.
DAWN
Updated: 24/09/2026, 18:19:08
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
No summaries found.
- Share price
- $21.53
- Market cap
- $2.22B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Jeremy Bender
- Employees
- 181
- IPO date
- 27/05/2021
- Beta
- -1.748
- Last dividend
- $0.00
- Day range
- $21.53 – $21.53
- 52-week range
- $5.64 – $21.53
- 1-day performance
- 0.00%
- 1-year performance
- 282.08%
- Current drawdown (1Y)
- 0.00%
- CIK
- 0001845337
- CUSIP
- 23954D109
- ISIN
- US23954D1090
- Created
- 07/12/2025, 03:32:13
- Last update
- 24/09/2026, 18:19:08
Track Day One Biopharmaceuticals, Inc. with an AI analyst
See which prediction-market events move DAWN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Servier completes the acquisition of Day One Biopharmaceuticals
PRNewsWire • STOCK • 23/04/2026, 10:30:00
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Business Wire • STOCK • 26/03/2026, 18:16:00
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Zacks Investment Research • STOCK • 09/03/2026, 11:11:10
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Business Wire • STOCK • 06/03/2026, 19:25:00
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)
Newsfile Corp • STOCK • 06/03/2026, 17:01:00
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
PRNewsWire • STOCK • 06/03/2026, 15:45:00
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)
PRNewsWire • STOCK • 06/03/2026, 14:12:00
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
GlobeNewsWire • STOCK • 06/03/2026, 09:30:00
Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth
Seeking Alpha • STOCK • 05/03/2026, 15:41:06
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
Seeking Alpha • STOCK • 27/02/2026, 16:29:35
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 25/02/2026, 07:11:30
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 24/02/2026, 21:31:53